Boston scientific received information that during a routine follow-up, oversensed noise was noted on the right ventricular channel which was stored as high rate ventricular events.This led to the patient receiving four bursts of anti-tachycardia pacing and a shock.A slight fluctuation in pacing impedances were also noted, but no measurements were out of range.The patient's device was later explanted and replaced without any further allegations made against it.No adverse patient effects were reported.
|
(b)(4).Upon receipt at our post market quality assurance laboratory, a review of device memory revealed that the device declared elective replacement indicator (eri) after experiencing two charge times greater than the charge time limit.End of life (eol) was declared following a single charge time greater than 30 seconds.The observed rate of battery usage was compared to the expected rate of battery usage and the results indicated the monitoring voltage was normal based on therapy use and programmed settings.It was concluded that this device did not experience premature battery depletion.Rather, the eri to eol time period was shortened due to a higher-than-typical buildup of internal battery impedance.The device was capable of detecting and treating arrhythmias, as the battery itself had sufficient capacity remaining to provide therapy if needed.Analysis was not able to confirm the previous allegations made against this device in the field.
|